ERBB2 and breast carcinoma: Oleuropein aglycone also synergistically enhanced down-regulation of HER2 expression mediated by trastuzumab and reversed acquired resistance to trastuzumab in SKBR3 cells, suggesting its potential use in the treatment of trastuzumab-resistant breast cancer [134].